When even the most highly trained surgeons perform procedures on the retina—one of the smallest, most delicate parts of the ...

The U.S. Food and Drug Administration has approved Genentech's Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular ... injections (9.6 and 9.4 eye chart letters, respectively). The most ...

6, 2025 — The FDA has approved a new implantable treatment for adults with diabetic macular edema ... that treats eye diseases, so patients don’t need frequent injections.

eye pain, cataract, conjunctival disorder, and vitreous hemorrhage. Susvimo is also indicated for the treatment of neovascular (wet) age-related macular degeneration in patients who have previously ...

Cataracts, dry eyes, glaucoma and other eye problems become more common with age. But these can be treated — and sometimes ...

a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing sustained vision improvements with fewer treatments than standard eye injections. The FDA has ...

Susvimo is the first and only FDA-approved treatment shown to maintain vision in people with DME with fewer treatments than standard-of-care eye injections. Susvimo is now available to US retina ...

Intravitreal injections, including those with Lucentis, have been associated with endophthalmitis, retinal detachment ... the most common ocular side effects included conjunctival hemorrhage, eye pain ...

“Susvimo presents a unique, convenient treatment alternative to routine eye injections ... hemorrhage. Susvimo is also indicated for the treatment of neovascular (wet) age-related macular ...

Susvimo is now available to U.S. retina specialists and their patients with DME. "Susvimo presents a unique, convenient treatment alternative to routine eye injections for people with a ...

4-6 Susvimo is now available to US retina specialists and their patients with DME. “Susvimo presents a unique, convenient treatment alternative to routine eye injections for people with a ...